Who Paid My Doc
Lashonda Spencer
Pediatric Infectious Diseases Los Angeles, CA Medical Doctor
NPI 1902904824 CMS profile 1214695
1640 Marengo St, Hra 300, Los Angeles, CA 90033
General payments
$122,659
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$127,072
Through program year 2025, Lashonda Spencer of Los Angeles, CA is reported in the CMS Open Payments database as having received $122,659 across 204 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $127,072 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $40,424 | 53 | |
| 2024 | General | $13,581 | 31 | |
| 2023 | General | $20,702 | 49 | |
| 2022 | General | $8,670 | 22 | |
| 2021 | General | $10,090 | 8 | |
| 2020 | General | $5,399 | 10 | |
| 2019 | General | $23,794 | 31 |
Beside peers
- Lashonda Spencer
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Lashonda Spencer were reported at $40,424. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Lashonda Spencer | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $23,794 | $175 | $34–$2,175 | $163 |
| 2020 | $5,399 | $521 | $34–$6,009 | $114 |
| 2021 | $10,090 | $1,077 | $39–$4,557 | $132 |
| 2022 | $8,670 | $232 | $53–$6,196 | $149 |
| 2023 | $20,702 | $140 | $52–$4,662 | $160 |
| 2024 | $13,581 | $198 | $52–$3,860 | $164 |
| 2025 | $40,424 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 37 drugsPart D claims
868
Drug cost
$1,059,695
Branded share of claims
51.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 86 | $325,298 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 46 | $160,105 | |
| Tivicay Dolutegravir Sodium | Brand | 48 | $119,266 | |
| Rukobia Fostemsavir Tromethamine | Brand | 11 | $112,989 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 51 | $108,983 | |
| Prezcobix Darunavir/Cobicistat | Brand | 30 | $74,848 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 16 | $62,294 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 12 | $45,898 | |
| Ozempic Semaglutide | Brand | 21 | $16,962 | |
| Eliquis Apixaban | Brand | 16 | $9,668 |
The 10 drugs with the highest cost, of 37 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
5 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Biktarvy |
|
$10,339 | 86 | — |
| Sunlenca |
|
$2,704 | — | — |
| APRETUDE |
|
$223 | — | — |
| PIFELTRO |
|
$28 | — | — |
| DELSTRIGO |
|
$28 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
204 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in California
James McCarty
Pediatric Infectious Diseases · Madera, CA
Antonio Arrieta
Pediatric Infectious Diseases · Orange, CA
John Bradley
Pediatric Infectious Diseases · San Diego, CA
Hayley Gans
Pediatric Infectious Diseases · Palo Alto, CA
Yvonne Maldonado
Pediatric Infectious Diseases · Stanford, CA
Audra Deveikis
Pediatric Infectious Diseases · Long Beach, CA
Related records
Pediatric Infectious Diseases in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.